Dr Kate Cwynarski

Telephone:

Email:

Location:

  • University College Hospital

Professional background

  • Trained at King's College, Hammersmith Hospital and Royal Free Hospitals
  • MRC Clinical Research Fellowship PhD at Imperial College, London

Specialties

Research interests

Specialist interests in Primary CNS lymphoma, HIV-related lymphoma and T-cell Lymphomas. Lead UK T cell Lymphoma Trials Group and prior lead of the UK CNSL group. Involved in clinical trials and member of the International Lymphoma Trials Groups.

Publications

  • TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial. Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine DA, Balasubramaniam N, Wood L, Shang J, Xue E, Zhang Y, Basilico S, Neves M, Raymond M, Scott I, El-Kholy M, Jha R, Dainton-Smith H, Hussain R, Day W, Ferrari M, Thomas S, Lilova K, Brugger W, Marafioti T, Lao-Sirieix P, Maciocia P, Pule M.Nat Med. 2024 Nov 11. doi: 10.1038/s41591-024-03326-7. Online ahead of print. PMID: 39528665
  • How I treat secondary CNS involvement by aggressive lymphomas. Alderuccio JP, Nayak L, Cwynarski K. Blood. 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168.
  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Ferreri AJM, Cwynarski K, Pulczynski E, …Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators.Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. (after publications of this trial as 2nd author/UK lead in The Lancet Haematology in 2016 and 2017)
  • MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Ferreri AJM, Doorduijn JK, Re A, … Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG).Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5 (resulting in senior author in invited Blood ‘How I treat secondary CNS involvement by aggressive lymphomas. Alderuccio JP, Nayak L, Cwynarski K. Blood. 2023 Nov 23;142(21):1771-1783. doi: 10.1182/blood.2023020168)
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study. Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM.Lancet Oncol. 2024 Oct 29:S1470-2045(24)00503-5. doi: 10.1016/S1470-2045(24)00503-5. Online ahead of print.PMID: 39486433
  • Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Hübel K, Bower M, Aurer I, Bastos-Oreiro M, Besson C, Brunnberg U, Cattaneo C, Collins S, Cwynarski K, Dalla Pria A, Hentrich M, Hoffmann C, Kersten MJ, Montoto S, Navarro JT, Oksenhendler E, Re A, Ribera JM, Schommers P, von Tresckow B, Buske C, Dreyling M, Davies A; EHA and ESMO Guidelines Committees. Electronic address: guidelines@ehaweb.org.Ann Oncol. 2024 Oct;35(10):840-859. doi: 10.1016/j.annonc.2024.06.003. Epub 2024 Sep 3.PMID: 39232987
  • Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results. Martelli M, Ceriani L, Ciccone G, Ricardi U, Kriachok I, Botto B, Balzarotti M, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka A, Ferreri AJM, Merli F, Zhao W, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, .. M, Johnson PWM, Davies A, Zucca E; International Extranodal Lymphoma Study Group (IELSG).J Clin Oncol. 2024 Aug 19:JCO2401373. doi: 10.1200/JCO-24-01373. Online ahead of print.PMID: 39159403
  • Central nervous system prophylaxis in large B-cell lymphoma: A British Society for Haematology Good Practice Paper. Wilson MR, Cwynarski K, Eyre TA, Smith J, Chaganti S, Fox CP, McKay P.Br J Haematol. 2024 Aug 11. doi: 10.1111/bjh.19686.
  • Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees. Ann Oncol. 2024 May 14:S0923-7534(23)05074- And Hemasphere. 2024 Jun 4;8(6):e89. doi: 10.1002/hem3.89
  • Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial. Chaganti S, Maycock S, McIlroy G, Jackson AE, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench DJ, Arumainathan A, Fox CP, Johnson RJ, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies AJ, Wright J, Burns S Dr, Laurence ADJ, Wheatley K, Menne T.Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847
  • Extending potentially curative options for older patients with PCNSL. Phillips EH, Cwynarski K. Lancet Haematol. 2024 Mar;11(3):e171-e173. doi: 10.1016/S2352-3026(24)00004-8. Epub 2024 Jan 29.
  • The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Fox CP, Chaganti S, McIlroy G, Barrington SF, Burton C, Cwynarski K, Eyre TA, Illidge T, Kalakonda N, Kuhnl A, McKay P, Davies AJ.Br J Haematol. 2024 Apr;204(4):1178-1192. doi: 10.1111/bjh.19273. Epub 2024 Jan 21.
  • Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time. Boyle S, Roddie C, O'Reilly M, Menne T, Norman J, Gibb A, Lugthart S, Chaganti S, Gonzalez Arias C, Jones C, Latif A, Uttenthal BJ, Seymour F, Osborne W, Springell D, Hardefeldt P, Yallop D, Thoulouli E, Bloor A, Besley C, Mathew A, Burns D, Cwynarski K, Sanderson R, Kuhnl A. Br J Haematol. 2024 Feb;204(2):507-513. doi: 10.1111/bjh.19157. Epub 2023 Oct 17.

  • The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N. Blood. 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348.

  • High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5.

  • Primary central nervous system lymphoma.Ferreri AJM, Calimeri T, Cwynarski K, Dietrich J, Grommes C, Hoang-Xuan K, Hu LS, Illerhaus G, Nayak L, Ponzoni M, Batchelor TT.Nat Rev Dis Primers. 2023 Jun 15;9(1):29. doi: 10.1038/s41572-023-00439-0.PMID: 37322012 Review.

  • International multicentre retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, Fail T, Nicholson E, Fletcher K, Linton KM, Parsons KE, Elmusharaf N, Eccersley L, Eyre TA, Chaganti S, Smith J, Thakrar N, Kutilina A, Calimeri T, Martinez-Calle N, El-Sharkawi D, Osborne W, Illerhaus G, Fox CP, Ferreri AJ, Schorb E, Cwynarski K.Haematologica. 2022 Oct 27. doi: 10.3324/haematol.2022.281640. PMID: 36300776

  • CNS prophylaxis for diffuse large B-cell lymphoma. Eyre TA, Savage KJ, Cheah CY, El-Galaly TC, Lewis KL, McKay P, Wilson MR, Evens AM, Bobillo S, Villa D, Maurer MJ, Cwynarski K, Ferreri AJM.Lancet Oncol. 2022 Sep;23(9):e416-e426. doi: 10.1016/S1470-2045(22)00371-0. PMID: 36055310 Review.

  • Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E… Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators.Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.

  • A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A.Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29.

  • Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Fox CP, Ahearne MJ, Pettengell R, Dearden C, El-Sharkawi D, Kassam S, Cook L, Cwynarski K, Illidge T, Collins G.Br J Haematol. 2021 Nov 2

  • CNS lymphoma: the TIER trial. Fox CP, Ali AS, McIlroy G, Thust S, Martinez-Calle N, Jackson AE, Hopkins LM, Thomas CM, Kassam S, Wright J, Auer DP, Cwynarski K. Blood Adv. 2021 Oct 26;5(20):4073-4082. doi: 10.1182/bloodadvances. 2021004779. PMID: 34464973

  • Advances in treatment of elderly primary central nervous system lymphoma. Martinez-Calle N, Isbell LK, Cwynarski K, Schorb E. Br J Haematol. 2021 Aug 26. doi: 10.1111/bjh.17799. Online ahead of print. PMID: 34448202

  • Sequencing therapies in Hodgkin lymphoma. Phillips EH, Collins GP, Cwynarski K. Lancet Haematol. 2021 Aug;8(8):e537-e539. doi: 10.1016/S2352-3026(21)00200-3.PMID: 34329571 Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP.Adv Ther. 2021 Jul;38(7):3789-3802. doi: 10.1007/s12325-021-01764-0. Epub 2021 May 26.

  • MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG).Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5.PMID: 33513372

  • HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Alderuccio JP, Olszewski AJ, Evens AM, …Lossos IS, Cwynarski K. Blood Adv. 2021 Jul 27;5(14):2852-2862. doi: 10.1182/bloodadvances.2021004458. (and associated paper in JCO 2021)

  • Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, .. Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup.N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10.PMID: 38078508 Clinical Trial